A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS) - Trial NCT06215755
Access comprehensive clinical trial information for NCT06215755 through Pure Global AI's free database. This Phase 1 trial is sponsored by Verge Genomics and is currently Recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Verge Genomics
Timeline & Enrollment
Phase 1
Jan 15, 2024
Jun 01, 2026
Primary Outcome
Number of Participants with Treatment-emergent Adverse Events (TEAEs),Number of Participants with Clinical Laboratory Evaluation Abnormalities,Number of Participants with Vital Sign Abnormalities,Number of Participants with Electrocardiogram (ECG) Abnormalities,Number of Participants with Physical Examination Abnormalities,Number of Participants with Neurological Examination Abnormalities
Summary
The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in
 participants with ALS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06215755
Non-Device Trial